These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30354399)

  • 81. Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
    Sarrias A; Bayes-Genis A
    Circulation; 2018 Aug; 138(6):551-553. PubMed ID: 30354612
    [No Abstract]   [Full Text] [Related]  

  • 82. Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
    James M; Manns B
    Circulation; 2018 Oct; 138(15):1515-1518. PubMed ID: 30354525
    [No Abstract]   [Full Text] [Related]  

  • 83. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives.
    Gori M; D'Elia E; Senni M
    Int J Cardiol; 2019 Apr; 281():158-165. PubMed ID: 30420146
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF.
    Suzuki T; Yazaki Y; Voors AA; Jones DJL; Chan DCS; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; Metra M; Ng LL
    Eur J Heart Fail; 2019 Jul; 21(7):877-886. PubMed ID: 30370976
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Novel Possibilities in Pharmacotherapy of Patients With Chronic Heart Failure].
    Zhuravleva MV; Prokofiev AB; Shih EV; Serebrova SY; Gorodetskaya GI
    Kardiologiia; 2018 Oct; (10):88-95. PubMed ID: 30359220
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
    [TBL] [Abstract][Full Text] [Related]  

  • 89. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.
    Parseghian CM; Loree JM; Morris VK; Liu X; Clifton KK; Napolitano S; Henry JT; Pereira AA; Vilar E; Johnson B; Kee B; Raghav K; Dasari A; Wu J; Garg N; Raymond VM; Banks KC; Talasaz AA; Lanman RB; Strickler JH; Hong DS; Corcoran RB; Overman MJ; Kopetz S
    Ann Oncol; 2019 Feb; 30(2):243-249. PubMed ID: 30462160
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.
    Maloney A; Rosenstock J; Fonseca V
    Clin Pharmacol Ther; 2019 May; 105(5):1213-1223. PubMed ID: 30457671
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.
    Lou-Meda R; Stiller B; Antonio ZL; Zielinska E; Yap HK; Kang HG; Tan M; Glazer RD; Valentin MA; Wang L
    Pediatr Nephrol; 2019 Mar; 34(3):495-506. PubMed ID: 30397789
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation.
    Zhao Z; Niu X; Dong Z; Qi W; Liu E; Liu T; Li L; Liang Y; Li G
    Cardiovasc Ther; 2018 Dec; 36(6):e12478. PubMed ID: 30390409
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Intraoperative prediction of cardiac surgery-associated acute kidney injury using urinary biomarkers of cell cycle arrest.
    Cummings JJ; Shaw AD; Shi J; Lopez MG; O'Neal JB; Billings FT
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1545-1553.e5. PubMed ID: 30389130
    [TBL] [Abstract][Full Text] [Related]  

  • 97. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
    Lingvay I; Handelsman Y; Linjawi S; Vilsbøll T; Halladin N; Ranc K; Liebl A
    Endocr Pract; 2019 Feb; 25(2):144-155. PubMed ID: 30383495
    [TBL] [Abstract][Full Text] [Related]  

  • 98. EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial.
    Girerd S; Frimat L; Ducloux D; Le Meur Y; Mariat C; Moulin B; Mousson C; Rieu P; Dali-Youcef N; Merckle L; Lepage X; Rossignol P; Girerd N; Jaisser F
    Trials; 2018 Oct; 19(1):595. PubMed ID: 30376884
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
    Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Eckel RH; Cannon CP; Lee LV; Bessac L; Pordy R; Letierce A; Ray KK
    J Am Heart Assoc; 2018 Sep; 7(18):e009221. PubMed ID: 30371190
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
    Gutierrez JA; Scirica BM; Bonaca MP; Steg PG; Mosenzon O; Hirshberg B; Im K; Raz I; Braunwald E; Bhatt DL
    Am J Cardiol; 2019 Jan; 123(1):145-152. PubMed ID: 30366601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.